Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 400
- Registration Number
- NCT01338545
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
Phase 3
Withdrawn
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01338558
A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]Drug: peginterferon alfa 2a [Pegasys]
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT01337375
An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 197
- Registration Number
- NCT01337388
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Phase 3
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1401
- Registration Number
- NCT01332968
- Locations
- 🇨🇦
North York General Hospital, Toronto, Ontario, Canada
🇦🇺St Vincent'S Hospital; Haematology, Fitzroy, Victoria, Australia
🇨🇦Humber River Hospital, Toronto, Ontario, Canada
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 220
- Registration Number
- NCT01332981
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 519
- Registration Number
- NCT01332994
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 423
- Registration Number
- NCT01333007
A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 381
- Registration Number
- NCT01331850
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3080
- Registration Number
- NCT01331837
- Locations
- 🇺🇸
Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
🇺🇸Apex Medical Research, AMR, Inc., Chicago, Illinois, United States
🇺🇸Columbus Arthritis Center, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath